InflaRx N.V. (IFRX)
2.34
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
2.34
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.47 |
| Market Cap | 137.79M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1 |
| PE Ratio (ttm) | -2.34 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.58 |
| Volume | 56,149 |
| Avg. Volume (20D) | 282,311 |
| Open | 2.37 |
| Previous Close | 2.34 |
| Day's Range | 2.30 - 2.46 |
| 52-Week Range | 1.17 - 2.81 |
| Beta | undefined |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III c...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 7, 2017
Employees 62
Stock Exchange NASDAQ
Ticker Symbol IFRX
Website https://www.inflarx.de
Analyst Forecast
According to 1 analyst ratings, the average rating for IFRX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 241.88% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
InflaRx N.V. is scheduled to release its earnings on Mar 20, 2025,
before market opens.
Analysts project revenue of $133.33K, reflecting a 5.32K% YoY growth and earnings per share of -0.28, making a -6.67% decrease YoY.
Analysts project revenue of $133.33K, reflecting a 5.32K% YoY growth and earnings per share of -0.28, making a -6.67% decrease YoY.
6 months ago ·
Source
+8.44%
InflaRx shares are trading higher after the compan...
Unlock content with
Pro Subscription
